Ed Newman

Edward Newman, Ph.D.

  • Associate Professor, Department of Cancer Biology

Edward Newman, Ph.D.

Research Focus :
  • The Mechanism of Reactivation of Tumor Suppressor Genes by Inhibitors of DNA (Cytosine-5) Methyltransferase
  • Mechanisms of Drug Resistance
Dr. Newman received his Ph.D. in Pharmacology from Yale University and completed a postdoctoral fellowship at UCSF prior to joining the faculty at City of Hope.  He is an Associate Professor in the Department of Cancer Biology.  He is the Principal Investigator of the California Cancer Consortium UM1 Cooperative Agreement, which supports participation by four California institutions (City of Hope, USC, UC Davis, and Stanford) in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN).  His laboratory and translational interests focus on the development of epigenetic-directed therapeutics.
  • Cancer Biology
  • Developmental Cancer Therapeutics Program
  • Comprehensive Cancer Center Co-leaders
  • Early Therapeutic Disease Team
  • Leukemia Disease Team
  • Lymphoma Disease Team
The Mechanism of Reactivation of Tumor Suppressor Genes by Inhibitors of DNA (Cytosine-5) Methyltransferase
The primary focus of my research program is the development of novel DNA (cytosine-5) methyltransferase (MT'ase) inhibitors for cancer therapy. An interest in both fluoropyrimidines and DNA methylation led to a collaboration with Dr. Steven Smith and Dr. Lawrence Sowers that demonstrated for the first time a covalent complex of human MT'ase with an oligonucleotide containing 5-fluoro-2'-deoxycytidine (FdCyd) and the methyl group from the cofactor AdoMet. We have continued to study the metabolism of FdCyd to FdCTP and the effects of its incorporation into cellular DNA on DNA methylation and gene expression.

Although FdCyd is rapidly degraded to FdUrd by cytidine/deoxycytidine deaminiase, this degradation can be inhibited by tetrahydrouridine (THU) without inhibiting its activation by deoxycytidine kinase. Thus, the effects of FdCyd on MT'ase and other potential intracellular targets can be examined in the presence of THU. Molecular studies of the gene activation profile of FdCyd have continued in my laboratory, and preclinical toxicology studies of the FdCyd/THU combination were performed utilizing the Animal Resources and Pathology core facilities. A detailed understanding of the mechanism by which FdCyd and other inhibitors of MT'ase result in a decrease in the methylation of cytosines in DNA is critical for the future development of this class of agents. The preclinical toxicology and other safety studies led to approval for the initial clinical studies of an Investigational New Drug (IND #54,223, 5-fluoro-2'-deoxycytidine) by the United States Food and Drug Administration (FDA).

In collaboration with Dr. James Doroshow, Dr. Robert Morgan, Jr., and other clinical investigators we conducted the first-in-human Phase I trial of the combination of FdCyd, and THU, patients with advanced solid tumors. In addition to the clinical objectives, pharmacokinetic studies of FdCyd in plasma and laboratory correlative studies were included in the protocol. With funding from the NCI and the Department of Defense Breast Cancer Research Program, we demonstrated the induction of fetal hemoglobin expression during treatment as surrogate marker for the biological activity of FdCyd.
Mechanisms of Drug Resistance
In collaboration with Dr. Robert Chen and Dr. Susan Kane, we are studying in vitro models of resistance to the antibody-drug conjugate brentuximab vedotin.  Current studies focus on mechanistically based possible drug combinations which may overcome resistance.

Somlo, G., Frankel, P.H.,  Arun, B.K., Ma, C.X., Garcia, A.A., Cigler, T., Cream, L.V., Harvey, H.A., Sparano, J.A., Nanda, R., Chew, H.K., Moynihan, T.J., Vahdat, L.T., Goetz, M.P., Beumer, J.H., Hurria, A., Mortimer, J., Piekarz, R., Sand, S., Herzog, J., Van Tongeren, L.R., Ferry-Galow, K.V., Chen, A.P., Ruel, C., Newman, E.M., Gandara, D.R., and Weitzel, J.N. Efficacy of the Poly (ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 (veliparib) Alone or in Combination with Carboplatin in Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer California Cancer Consortium Trial NCT01149083. Clin. Cancer Res. 23, 4066-4076, 2017. PMID: 28356425. PMCID: PMC5540749

“Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. PubMed PMID: 25567350; PubMed Central PMCID: PMC4344391”
Back To Top